← Back to Search

CAR T-cell Therapy

Anti-BCMA CAR T Cell Therapy for Multiple Myeloma

Phase 1 & 2
Waitlist Available
Research Sponsored by Allogene Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented diagnosis of relapsed/refractory multiple myeloma (MM)
Subjects must have received ≥3 prior MM lines of therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months of study follow-up
Awards & highlights

Study Summary

This trial is testing a new cancer treatment on adults with relapsed or refractory multiple myeloma.

Who is the study for?
This trial is for adults with relapsed or refractory multiple myeloma who have tried at least three other treatments and still have measurable disease. They should be relatively healthy, with a life expectancy of at least 3 months without treatment, and good heart, lung, kidney, liver, and blood function.Check my eligibility
What is being tested?
The study tests ALLO-605 CAR T cell therapy after patients receive a lymphodepletion regimen (a process to reduce white blood cells) that includes fludarabine, cyclophosphamide, and ALLO-647. The goal is to see how safe it is and how well it works against multiple myeloma.See study design
What are the potential side effects?
Possible side effects may include reactions related to the immune system attacking normal cells while targeting cancer cells (like inflammation), as well as those associated with chemotherapy such as nausea, fatigue, low blood counts leading to increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My multiple myeloma has come back or didn't respond to treatment.
Select...
I have undergone 3 or more treatments for multiple myeloma.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months of study follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months of study follow-up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1: Proportion of patients experiencing Dose Limiting Toxicities with ALLO-647 [administered in combination with fludarabine/cyclophosphamide administered prior to ALLO-605]
Phase 1: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-605 that will determine MTD/MAD and select the recommended Phase 2 dose (RP2D) of ALLO-605.
Phase 2: To assess clinical efficacy of ALLO-605 as measured by overall response rate (ORR)

Trial Design

1Treatment groups
Experimental Treatment
Group I: ALLO-605, ALLO-647Experimental Treatment4 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~3770
Fludarabine
2012
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Allogene TherapeuticsLead Sponsor
5 Previous Clinical Trials
556 Total Patients Enrolled
1 Trials studying Multiple Myeloma
132 Patients Enrolled for Multiple Myeloma

Media Library

ALLO-605 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05000450 — Phase 1 & 2
ALLO-605 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05000450 — Phase 1 & 2
Multiple Myeloma Clinical Trial 2023: ALLO-605 Highlights & Side Effects. Trial Name: NCT05000450 — Phase 1 & 2
Multiple Myeloma Research Study Groups: ALLO-605, ALLO-647

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any prior experiments that have employed ALLO-605?

"The first research trial of ALLO-605 began at the City of Hope Comprehensive Cancer Center in 1997. To date, 1275 trials have been concluded and 889 are still underway across Houston and Colorado."

Answered by AI

Is there a widespread research effort to evaluate this therapy in multiple locations within the state?

"This project is currently enrolling participants at 4 locales, namely Houston, Austin and Denver in addition to another site. To reduce travel needs if selected for the study, it's best to pick a medical centre that is closest you."

Answered by AI

What is the aggregate number of participants in this research endeavor?

"Affirmative. Information published on clinicaltrials.gov states that this study, which was posted for the first time on June 6th 2021, is currently seeking participants. The research team aim to admit 136 patients from 4 different medical sites."

Answered by AI

Are any volunteers being accepted for this experiment?

"According to clinicaltrials.gov, this medical experiment is still in the recruitment stage and was initially advertised on June 6th 2021 before being revised on February 9th 2022."

Answered by AI

What maladies have been ameliorated by ALLO-605?

"ALLO-605 is a common drug for managing multiple sclerosis, but it can also be used on lymphoma, leukemia, myelocytic and acute forms of cancer. Additionally, retinoblastoma patients may find some relief with this medication."

Answered by AI

Who else is applying?

What state do they live in?
Missouri
California
How old are they?
18 - 65
What site did they apply to?
Sarah Cannon/Colorado Blood Cancer Institute
St. David's South Austin Medical Center
MD Anderson Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
2021. "Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05000450.
~40 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top